The transcription factor ATF4 regulates glucose metabolism in mice through its expression in osteoblasts

Journal of Clinical Investigation

Volumn 119, Issue 9, 2009, Pages 2807-2817

  Yoshizawa, Tatsuya ^a   Hinoi, Eiichi ^a   Dae, Young Jung ^b   Kajimura, Daisuke ^a   Ferron, Mathieu ^a   Seo, Jin ^c   Graff, Jonathan M ^c   Kim, Jason K ^b   Karsenty, Gerard ^a,d  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d HHSC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; GLUCOSE; OSTEOCALCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MASS; CONTROLLED STUDY; ENERGY METABOLISM; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GLUCOSE METABOLISM; INSULIN SENSITIVITY; MOLECULAR MODEL; MOUSE; NONHUMAN; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

ACTIVATING TRANSCRIPTION FACTOR 4; ANIMALS; GENE EXPRESSION; GLUCOSE; INSULIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOCALCIN; PHENOTYPE;

EID: 70349226800     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI39366     Document Type: Article

References (34)

1. Karsenty, G., and Wagner, E.F. 2002. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell. 2:389-406. (Pubitemid 34436569)
2. Ducy, P., Zhang, R., Geoffroy, V., Ridall, A.L., and Karsenty, G. 1997. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 89:747-754. (Pubitemid 27516177)
3. Nakashima, K., et al. 2002. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 108:17-29. (Pubitemid 34137009)
4. Yang, X., et al. 2004. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell. 117:387-398. (Pubitemid 38534544)
5. Yang, X., and Karsenty, G. 2004. ATF4, the osteoblast accumulation of which is determined posttranslationally, can induce osteoblast-specific gene expression in non-osteoblastic cells. J. Biol. Chem. 279:47109-47114. (Pubitemid 39518367)
6. Harding, H.P., et al. 2003. An integrated stress response regulates amino acid metabolism and resistance to cxidative stress. Mol. Cell. 11:619-633.
7. Elefteriou, F., et al. 2006. ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab. 4:441-451. (Pubitemid 44817348)
8. Teitelbaum, S.L., and Ross, F.P. 2003. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4:638-679.
9. Elefteriou, F., et al. 2005. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 434:514-520. (Pubitemid 40477060)
10. Lee, N.K., et al. 2007. Endocrine regulation of energy metabolism by the skeleton. Cell. 130:456-469.
11. Ferron, M., Hinoi, E., Karsenty, G., and Ducy, P. 2008. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc. Natl. Acad. Sci. U. S. A. 105:5266-5270. (Pubitemid 351738545)
12. Hinoi, E., et al. 2008. The sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity. J. Cell Biol. 183:1235-1242.
13. Delépine, M., et al. 2000. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat. Genet. 25:406-409. (Pubitemid 32983431)
14. -/- mice reveals a role for translational control in secretory cell survival. Mol. Cell. 7:1153-1163.
15. Scheuner, D., et al. 2001. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol. Cell. 7:1165-1176. (Pubitemid 32607351)
16. Ron, D., and Walter, P. 2007. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8:519-529. (Pubitemid 46985379)
17. Oyadomari, S., Harding, H.P., Zhang, Y., Oyadomari, M., and Ron, D. 2008. Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice. Cell Metab. 7:520-532. (Pubitemid 351729207)
18. Yadav, V.K., et al. 2008. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum: an entero-bone endocrine axis. Cell. 135:825-837.
19. Unger, R.H. 1985. Glucagon physiology and pathophysiology in the light of new advances. Diabetologia. 28:574-578.
20. Puigserver, P., et al. 2003. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature. 423:550-555. (Pubitemid 36648580)
21. Granner, D., Andreone, T., Sasaki, K., and Beale, E. 1983. Inhibition of transcription of the phosphoenolpyruvate carboxykinase gene by insulin. Nature. 305:549-551.
22. Dickens, M., Svitek, C.A., Culbert, A.A., O'Brien, R.M., and Tavare, J.M. 1998. Central role for phosphatidylinositide 3-kinase in the repression of glucose-6-phosphatase gene transcription by insulin. J. Biol. Chem. 273:20144-20149. (Pubitemid 28377571)
23. Wolfrum, C., Asilmaz, E., Luca, E., Friedman, J.M., and Stoffel, M. 2004. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature. 432:1027-1032. (Pubitemid 40052233)
24. Iynedjian, P.B., et al. 1989. Differential expression and regulation of the glucokinase gene in liver and islets of Langerhans. Proc. Natl. Acad. Sci. U. S. A. 86:7838-7842. (Pubitemid 19265281)
25. Huang, B., Wu, P., Bowker-Kinley, M.M., and Harris, R.A. 2002. Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator- activated receptor- ligands, glucocorticoids, and insulin. Diabetes. 51:276-283. (Pubitemid 34764781)
26. Taniguchi, C.M., Emanuelli, B., and Kahn, C.R. 2006. Critical nodes in signaling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7:85-96. (Pubitemid 43278292)
27. Tolwani, R.J., et al. 2005. Medium-chain acyl-CoA dehydrogenase deficiency in gene-targeted mice. PLoS Genet. 1:e23.
28. Tontonoz, P., and Spiegelman, B.M. 2008. Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem. 77:289-312.
29. Rane, S.G., et al. 1999. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat. Genet. 22:44-52.
30. Dacquin, R., Starbuck, M., Schinke, T., and Karsenty, G. 2002. Mouse alpha1(I)-collagen promoter is the best known promoter to drive efficient Cre recombinase expression in osteoblast. Dev. Dyn. 224:245-251. (Pubitemid 34569065)
31. Price, P.A., and Kaneda, Y. 1987. Vitamin K counteracts the effect of warfarin in liver but not in bone. Thromb. Res. 46:121-131. (Pubitemid 17068374)
32. Mantamadiotis, T., et al. 2002. Disruption of CREB function in brain leads to neurodegeneration. Nat. Genet. 31:47-54. (Pubitemid 34887637)
33. Dacquin, R., et al. 2004. Knock-in nuclear localized beta-galactosidase reveals that the tyrosine phosphatase Ptprv is specifically expressed in cells of the bone collar. Dev. Dyn. 229:826-834. (Pubitemid 38429111)
34. Ueki, K., et al. 2000. Restored insulin-sensitivity in IRS-1-deficient mice treated by adenovirus-mediated gene therapy. J. Clin. Invest. 105:1437-1445. (Pubitemid 30322409)